Pacific Biosciences of California Management
Management criteria checks 2/4
Pacific Biosciences of California's CEO is Christian O. Henry, appointed in Sep 2020, has a tenure of 4.42 years. total yearly compensation is $8.05M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $718.66K. The average tenure of the management team and the board of directors is 4.1 years and 12 years respectively.
Key information
Christian O. Henry
Chief executive officer
US$8.0m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 4.4yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.1yrs |
| Board average tenure | 12yrs |
Recent management updates
Recent updates
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Might Not Be As Mispriced As It Looks After Plunging 26%
Feb 08
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 93% Above Its Share Price
Dec 10Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Nov 12Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company
Nov 07Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?
Oct 16Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely
Sep 20Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing
Aug 21Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper
Jul 02We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt
Jun 08Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas
Jun 03These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat
Apr 25It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?
Jul 31Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Jul 06Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Mar 29Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?
Feb 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$309m |
| Sep 30 2024 | n/a | n/a | -US$394m |
| Jun 30 2024 | n/a | n/a | -US$400m |
| Mar 31 2024 | n/a | n/a | -US$297m |
| Dec 31 2023 | US$8m | US$695k | -US$307m |
| Sep 30 2023 | n/a | n/a | -US$309m |
| Jun 30 2023 | n/a | n/a | -US$319m |
| Mar 31 2023 | n/a | n/a | -US$321m |
| Dec 31 2022 | US$7m | US$667k | -US$314m |
| Sep 30 2022 | n/a | n/a | -US$299m |
| Jun 30 2022 | n/a | n/a | -US$206m |
| Mar 31 2022 | n/a | n/a | -US$175m |
| Dec 31 2021 | US$3m | US$650k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$59m |
| Dec 31 2020 | US$13m | US$195k | US$29m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$51m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$100k | n/a | -US$84m |
| Sep 30 2019 | n/a | n/a | -US$115m |
| Jun 30 2019 | n/a | n/a | -US$111m |
| Mar 31 2019 | n/a | n/a | -US$109m |
| Dec 31 2018 | US$88k | n/a | -US$103m |
Compensation vs Market: Christian O.'s total compensation ($USD8.05M) is above average for companies of similar size in the US market ($USD2.12M).
Compensation vs Earnings: Christian O.'s compensation has increased whilst the company is unprofitable.
CEO
Christian O. Henry (56 yo)
4.4yrs
Tenure
US$8,046,575
Compensation
Mr. Christian O. Henry, MBA, is Independent Director of Ginkgo Bioworks Holdings, Inc. from 2016. He served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.4yrs | US$8.05m | 0.13% $ 718.7k | |
| Chief Operating Officer | 4.1yrs | US$4.60m | 0.12% $ 678.5k | |
| Co-Founder | 24.6yrs | US$466.76k | no data | |
| VP & Chief Accounting Officer | 3.8yrs | no data | 0.012% $ 67.0k | |
| General Counsel & Corporate Secretary | no data | no data | no data | |
| Global Head of Sales & Service | no data | no data | no data | |
| Chief People Officer | no data | no data | no data |
4.1yrs
Average Tenure
53yo
Average Age
Experienced Management: PACB's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$8.05m | 0.13% $ 718.7k | |
| Independent Director | 21.1yrs | US$259.00k | 0.0064% $ 34.8k | |
| Independent Director | 12.4yrs | US$255.00k | 0% $ 0 | |
| Independent Chairman | 11.6yrs | US$297.00k | 0.037% $ 203.5k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 16.1yrs | US$265.00k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 2.3yrs | no data | no data |
12.0yrs
Average Tenure
70yo
Average Age
Experienced Board: PACB's board of directors are seasoned and experienced ( 12 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 09:00 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pacific Biosciences of California, Inc. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Kyle Mikson | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |